Clinical effect of balofloxacin on obstetric and gynecological infections

DOI 4 References
  • Chimura Tetsuro
    Department of Obstetrics and Gynecology, School of Medicine, Yamagata University
  • Hirayama Toshio
    Department of Obstetrics and Gynecology, School of Medicine, Yamagata University
  • Oda Takahare
    Department of Obstetrics and Gynecology, Yamagata Prefectural Kahoku Hospital
  • Morisaki Nobuyuki
    Department of Obstetrics and Gynecology, Sendai Tokushukai Hospital
  • Murayama Kazuhiko
    Department of Obstetrics and Gynecology, Shinoda General Medical Hospital

Bibliographic Information

Other Title
  • Balofloxacinの産婦人科領域感染症に対する臨床効果の検討

Search this article

Abstract

Balofloxacin (BLFX), a new quinolone, was evaluated for its clinical efficacy and safety in obstetric and gynecologic infections. BLFX was given to a total of 13 patients (7 with intrauterine infection, 2 with adnexitis, 3 with genital infection, 1 with mastitis) orally at a dose of 100 or 200mg b. i. d. for 4-7 days.<BR>The clinical effect was good in all of 13 patients, and the efficacy rate was 100%. The bacteriological effect against 14 isolated strains was rated as eradicated in 13 and unchanged in 1; the eradication rate was 92.9% (13/14).<BR>Neither side effects nor abnormal laboratory findings were observed. BLFX was suggested to be useful in obstetric and gynecologic infections.

Journal

References(4)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top